CTLA4 and hypophysitis: Anti-CTLA-4 monotherapy exhibited a higher association with hypophysitis (leading to hypopituitarism) and adrenal insufficiency, while anti-PD-1/PD-L1 monotherapy was found to be predominantly linked to thyroid dysfunction and type 1 diabetes mellitus.